Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer
The FDA has approved durvalumab (Imfinzi) for the treatment of limited-stage small cell lung cancer (SCLC) that has not progressed following platinum-based concurrent chemoradiotherapy. The approval is supported by the phase 3 ADRIATIC study (NCT03703297). …